drugset
drugset / Trial / NCT05727800

A Phase 1, First-in-human Study of VX-668

NCT05727800 ↗

Phase 1 Completed 114 enrolled Vertex Pharmaceuticals Incorporated
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-668 at various doses.

Timeline

Start
2023-02-08
Primary completion
2023-09-12
Completion
2024-02-13

Drugs

EvaluationDrugModalityDoseRoute
Subject VX-668 Unknown — Oral

Indications

alpha 1-antitrypsin deficiency